Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case–control study
- 408 Downloads
Janus kinases (JAKs) are non-receptor protein tyrosine kinases that are expressed in many tissues. Once the JAKs are activated, a cascade of further signaling events is triggered involving phosphorylation of selected receptor chain tyrosines, binding of signal transducer and activator of transcription (STAT) proteins and phosphorylation of these STATs. Due to their ability to selectively modulate immune function, targeted JAK inhibitors are promising candidates for some skin diseases such as psoriasis and atopic dermatitis. The aim of this study was to assess the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases. This study was conducted on 10 patients with psoriasis, 10 patients with vitiligo and 10 controls. JAK1 levels before and after treatment with NB-UVB 311 nm (36 sessions) were measured using Western blot assay. The level of JAK1 was significantly higher in vitiligo and psoriasis patients than controls. There was a decline in the level of JAK1 after treatment, which was statistically significant. VASI and PASI scores of patients decreased after treatment with NB-UVB. In psoriatic patients, the JAK1 level positively correlated with the female participants, disease duration and PASI change. It was concluded that JAK1 plays a role in the pathogenesis of both vitiligo and psoriasis based on its upregulated level before treatment and downregulated level after treatment. This raises the possibility of using the JAK1 inhibitors as targeted immunotherapy for vitiligo and psoriasis.
KeywordsJAK Psoriasis Vitiligo NB-UVB JAK inhibitors
C-C motif chemokine ligand
Ciliary neurotrophic factor-receptor
Chemokine (C-X-C motif) ligand
Leukemia inhibitory factor-receptor
Narrow band ultraviolet B
Novel neurotrophin-1/B cell-stimulating factor-3 receptor
- OSM-R/ CT-1R
Psoriasis area and severity index
Protein tyrosine kinase
Signal transducer and activator of transcription
Tumor necrosis factor-alpha
Vitiligo area and severity index
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflicts of interest.
The authors did not receive any external funding for this work.
All procedures performed in the study were in accordance to the ethical standards of the Dermatology Research Ethical Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
A written informed consent was obtained from each patient for the participation in the study and photography.
- 14.Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74(2):370–371. https://doi.org/10.1016/j.jaad.2015.09.073 CrossRefPubMedGoogle Scholar
- 15.Hsu L, Armstrong AW (2014) JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014: 283617. https://doi.org/10.1155/2014/283617
- 17.Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC (2010) Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 23:276–286. https://doi.org/10.1111/j.1755-148X.2010.00688.x CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, Watson J, Wilson P, Simeoni M, Schifano LA, Reich K, Griffiths CE (2016) Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol 174:985–995. https://doi.org/10.1111/bjd.14399 CrossRefPubMedGoogle Scholar
- 23.Marks R, Barton SP, Shuttleworth D, Finlay AY (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125:235–240. https://doi.org/10.1001/archderm.1989.01670140087017 CrossRefPubMedGoogle Scholar
- 25.Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, Zhang X, Janes JM (2016) A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 174(6):1266–1276. https://doi.org/10.1111/bjd.14403 CrossRefPubMedGoogle Scholar
- 29.Nasr Seif El, Shaker H, Fawzi OG, El-Hanafi MM G (2013) Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. J Eur Acad Dermatol Venereol 27:103–108. https://doi.org/10.1111/j.1468-3083.2011.04368.x CrossRefGoogle Scholar
- 30.Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W et al (2013) A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 191:2205–2216. https://doi.org/10.4049/jimmunol.1202859 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129:2220–2232. https://doi.org/10.1038/jid.2009.32 CrossRefPubMedGoogle Scholar